Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

被引:30
作者
Timmins, Hannah C. [1 ]
Mizrahi, David [2 ]
Li, Tiffany [1 ]
Kiernan, Matthew C. [1 ,3 ,4 ]
Goldstein, David [2 ,5 ]
Park, Susanna B. [1 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Sydney, NSW, Australia
[2] UNSW Sydney, Fac Med, Prince Wales Clin Sch, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW, Australia
[5] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
Chemotherapy; Neuropathy; Risk factors; Obesity; Diabetes; Physical activity; QUALITY-OF-LIFE; CANCER-PATIENTS; COLORECTAL-CANCER; PHYSICAL-ACTIVITY; BREAST-CANCER; SENSORY NEUROPATHY; BODY-MASS; EXERCISE; SURVIVORS; WOMEN;
D O I
10.1007/s11764-021-00988-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common dose-limiting toxicity of cancer treatment causing functional impairment and impacting quality of life. Effective prevention and treatment of CIPN are lacking, and CIPN risk factors remain ill-defined. Metabolic syndrome and associated conditions have emerged as potential risk factors, due to their high prevalence and independent association with nerve dysfunction. This systematic review aimed to investigate the association between these common metabolic-lifestyle factors and CIPN. Methods Searches were undertaken using Medline, Embase, CINAHL, Scopus, and Web of Science databases, with additional studies identified from bibliographic references cited by original and review articles. Articles that analyzed metabolic-lifestyle risk factors associated with CIPN for patients treated with platinum- or taxane-based chemotherapy were included. Results Searches identified 6897 titles; 44 articles had full text review, with 26 studies included. Overall incidence of neuropathy ranged from 16.9 to 89.4%. Obesity had the most consistent patient-oriented evidence as a risk factor for CIPN, with moderate evidence suggesting diabetes did not increase CIPN incidence or severity. A limited number of studies supported an association with low physical activity and greater CIPN risk. Conclusions Comorbidities and lifestyle factors, particularly obesity and low physical activity, may contribute to the development of CIPN. The implementation of sensitive outcome measures in large-scale clinical trials is required to further elucidate CIPN risk factors and evaluate if changes in lifestyle would improve long-term CIPN outcomes for cancer survivors. Implications for Cancer Survivors Better understanding of CIPN risk profiles may inform personalized medicine strategies and help elucidate pathophysiological mechanisms which could be targeted for neuroprotection.
引用
收藏
页码:222 / 236
页数:15
相关论文
共 67 条
[1]   Predicting Acute and Persistent Neuropathy Associated With Oxaliplatin [J].
Alejandro, Linh M. ;
Behrendt, Carolyn E. ;
Chen, Kim ;
Openshaw, Harry ;
Shibata, Stephen .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (04) :331-337
[2]   Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens [J].
Ali, Raafi ;
Baracos, Vickie E. ;
Sawyer, Michael B. ;
Bianchi, Laurent ;
Roberts, Sarah ;
Assenat, Eric ;
Mollevi, Caroline ;
Senesse, Pierre .
CANCER MEDICINE, 2016, 5 (04) :607-616
[3]  
[Anonymous], 2019, International Diabetes Federation Diabetes Atlas, V9th
[4]   Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings [J].
Argyriou, Andreas A. ;
Park, Susanna B. ;
Islam, Badrul ;
Tamburin, Stefano ;
Velasco, Roser ;
Alberti, Paola ;
Bruna, Jordi ;
Psimaras, Dimitri ;
Cavaletti, Guido ;
Cornblath, David R. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (12) :1361-1369
[5]   Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101 [J].
Barginear, Myra ;
Dueck, Amylou C. ;
Allred, Jacob B. ;
Bunnell, Craig ;
Cohen, Harvey J. ;
Freedman, Rachel A. ;
Hurria, Arti ;
Kimmick, Gretchen ;
Le-Rademacher, Jennifer G. ;
Lichtman, Stuart ;
Muss, Hyman B. ;
Shulman, Lawrence N. ;
Copur, M. Sitiki ;
Biggs, David ;
Ramaswamy, Bhuvaneswari ;
Lafky, Jacqueline M. ;
Jatoi, Aminah .
ONCOLOGIST, 2019, 24 (05) :617-623
[6]  
Bertin E, 2000, DIABETES METAB, V26, P178
[7]   Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience [J].
Bhatnagar, Bhavana ;
Gilmore, Steven ;
Goloubeva, Olga ;
Pelser, Colleen ;
Medeiros, Michelle ;
Chumsri, Saranya ;
Tkaczuk, Katherine ;
Edelman, Martin ;
Bao, Ting .
SPRINGERPLUS, 2014, 3 :1-6
[8]   Obesity: global epidemiology and pathogenesis [J].
Blueher, Matthias .
NATURE REVIEWS ENDOCRINOLOGY, 2019, 15 (05) :288-298
[9]  
Bray GA, 2014, OBESITY ADULTS PREVA
[10]   Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance) [J].
Brown, Justin C. ;
Zhang, Sui ;
Ou, Fang-Shu ;
Venook, Alan P. ;
Niedzwiecki, Donna ;
Lenz, Heinz-Josef ;
Innocenti, Federico ;
O'Neil, Bert H. ;
Shaw, James E. ;
Polite, Blase N. ;
Denlinger, Crystal S. ;
Atkins, James N. ;
Goldberg, Richard M. ;
Ng, Kimmie ;
Mayer, Robert J. ;
Blanke, Charles D. ;
O'Reilly, Eileen M. ;
Fuchs, Charles S. ;
Meyerhardt, Jeffrey A. .
JNCI CANCER SPECTRUM, 2020, 4 (01)